Influenza Vaccination in Solid Organ Tranplant Recipients Open Access

[摘要] Immunogenicity of intramuscular influenza vaccine is suboptimal in organ transplant recipients although intradermal vaccine may be superior by targeting dermal dendritic cells to stimulate a response. 229 patients were randomized to IM or high-dose ID vaccine during the 2010-11 season. Pre- and 1 month post-vaccine bloodwork measured serology by hemagglutination inhibition assay (for influenza A/H1N1, A/H3N2 and B strains) and HLA antibody. Seroconversion was defined as a 4-fold rise in titer. Median time from transplant was 4.9 years. In 212 evaluable patients (105 IM, 107 ID), seroconversion to at least one antigen was 46.7% & 51.4% respectively (p=0.5). Seroconversion to at least 1 antigen was greater if i) ≥ 6 months post-transplant (53.2% vs. 19.2%; p=0.001) or ii) on <2g of mycophenolate mofetil (60.0% vs. 36.7%; p=0.001). Our study suggests that intradermal vaccine is safe, may be more immunogenic in selected subgroups and does not increase clinically relevant HLA antibody.

[发布机构] University of Alberta

[效力级别] Influenza